---

Early administration of Ivermectin, Azithromycin & Doxycycline along with I.V. Prednisolone in a case of COVID -19 disease may lead to early recovery?

Full Text PDF

---

Case Report

Author Details : Anisha Prasad*

Volume : 7, Issue : 3, Year : 2020

Article Page : 149-150

https://doi.org/10.18231/j.ijpca.2020.023

Suggest article by email

Get Permission

Abstract

A case of high-grade fever with chills for 5 days with shortness of breath since 12 an hour and mild abdominal discomfort is being presented in this report. A 62-year-old female doctor who was a known asthmatic for the last 20 years (on Seretide accuhaler S.O.S) presented with a history of heat exhaustion 7 days back, no history of nausea/vomiting/diarrhoea/sore throat or cough. Clinical examination revealed a fever of 101.8^®F, SpO2- 94%, blood pressure of 100/70, and pulse rate of 100/min. Breath sounds were normal vesicular, heart sounds normal and no murmur present. In investigations, Real-time PCR for COVID-19 was done on 02/06/20 and came out to be positive. HRCT chest revealed few multifocal
patchy areas of subpleural ground-glass haze in both the lungs with associated patchy fibrosis. She was treated with Azithromycin (500 mg OD x 5 days) and Ivermectin (6mg BD x 3 days /orally) along with Doxycycline 100 mg BD x 5 days and high flow oxygen. Prednisolone 50 mg/I.V. OD for 5 days followed by Dexamethasone (6mg P.O. and Monocef 1.5 gm x I.V. x BD x 5 days were added when SpO2 of less than 90% was recorded and the patient complained of breathlessness and chest discomfort. A repeat test for COVID -19 was done on 20.06.20 which came out to be positive followed by a third test on 22.06.20 which came out negative. The patient recovered after 15 days of admission and was requested to get a repeat CT
chest / Xray done after a month.

Keywords: Dexamethasone, Azithromycin, Doxycycline, COVID 19.

How to cite : Prasad A , Early administration of Ivermectin, Azithromycin & Doxycycline along with I.V. Prednisolone in a case of COVID -19 disease may lead to early recovery?. Int J Pharm Chem Anal 2020;7(3):149-150

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.